1 材料与方法
1.1 FEA的制备和试剂
1.2 病毒和细胞
1.3 试验设计
1.4 PCV2的增殖和鉴定
1.5 CCK8法检测3D4/2细胞活力
1.6 ELISA检测炎性因子及相关酶活性
1.7 定量PCR(q-PCR)检测mRNA的表达
表1 基因序列Table 1 Gene sequences |
| 基因 Genes | 序列 Sequence (5'—3') | 登录号 Accession No. | 产物大小 Product size/bp |
|---|---|---|---|
| 白细胞介素-6 IL-6 | F:GGCTGCTTCTGGTGATGG R:AGAGATTTTGCCGAGGATGTA | NM_214399.1 | 146 |
| 白细胞介素-10 IL-10 | F:TGAAGAGTGCCTTTACCAAGCTC R:CTCATCTTCATCGTCATGTAGGC | NM_214041.1 | 106 |
| 环氧合酶-2 COX-2 | F:CTGAACACCTCCGCTTTGC R:AAGCACATCGCACACTCTATTATGT | NM_214321.1 | 110 |
| c-fos | F:AGAATCCGAAGGGAAAGGAA R:AGATCAAGGGAAGCCACAGA | NM_001123113.1 | 248 |
| c-jun | F:CCCCTGTCCCCCATCGACATG R:TTGCAACTGCTGCGTTAGCAT | NM_213880.1 | 267 |
| c-myc | F:CTCTGACTCGCTGTAGTAATTCCAG R:TGTTGTAAGTTCCAGTGGAAAGTAC | NM_001005154.1 | 273 |
| p38丝裂原活化蛋白激酶 p38 MAPK | F:TCTGTAGGAAATCACACTAGC R:GTATGCACTTCAGATCTTCAC | XM_003356615.4 | 89 |
| 细胞外调节蛋白激酶 ERK | F:GACGCAGCACCTCAGCAA R:CACGGGCCAACCCAAAGT | XM_021071922.1 | 167 |
| 甘油醛-3-磷酸脱氢酶 GAPDH | F:ACATGGCCTCCAAGGAGTAAGA R:GATCGAGTTGGGGCTGTGACT | XM_021091114.1 | 106 |
1.8 Western Blotting检测蛋白表达水平
1.9 统计分析
2 结果
2.1 PCV2的增殖和鉴定
图1 PCV2的增殖及鉴定C为未感染PCV2的PK-15细胞;1~5分别为PK-15细胞感染后4、8、12、24、48 h;6为阳性对照;M为DNA Marker。 Fig.1 Proliferation and identification of PCV2 C mean PK-15 cells without PCV2 infection; 1 to 5 mean infection with PCV2 at 4, 8, 12, 24 and 48 h, respectively; 6 mean positive control, and M mean DNA marker. |
2.2 FEA对3D4/2细胞的细胞活力的影响
表2 FEA对3D4/2细胞的细胞活力的影响Table 2 Effects of FEA on cell viability of 3D4/2 cells |
| 项目 Item | 空白对照组 Blank control group | FEA浓度 FEA concentration/(μg/mL) | |||||
|---|---|---|---|---|---|---|---|
| 800 | 400 | 200 | 100 | 50 | 25 | ||
| 细胞活力 Cell viability | 100.0±15.6 | 71.7±2.9** | 61.4±4.9** | 73.8±7.8** | 104.9±12.6 | 99.1±0.1 | 106.3±0.7 |
**表示与空白对照组相比差异极显著(P<0.01)。 | |
** mean significant difference compared with the blank control group (P<0.01). |
2.3 FEA对PCV2感染3D4/2细胞的炎症细胞因子水平和相关酶的活性的影响
图2 FEA对PCV2感染3D4/2细胞的炎症细胞因子含量和相关酶活性的影响Control:空白对照组;PCV2:PCV2感染组;LPS:LPS阳性对照组;Rutin:芦丁阳性对照组;FEA25:25 μg/mL FEA药物组;FEA50:50 μg/mL FEA药物组;FEA100:100 μg/mL FEA药物组。*表示与空白对照组相比差异显著(P<0.05),**表示与空白对照组相比差异极显著(P<0.01);#表示与PCV2感染组相比差异显著(P<0.0 5),##表示与PCV2感染组相比差异极显著(P<0.01)。下图同。 Fig.2 Effects of FEA on inflammatory cytokine contents and related enzyme activities in PCV2-infected 3D4/2 cells Control: blank control group; PCV2: PCV2 infection group; LPS: LPS positive control group; Rutin: rutin positive control group; FEA25: 25 μg/mL FEA drug group; FEA50: 50 μg/mL FEA drug group; FEA100: 100 μg/mL FEA drug group. * mean significant difference compared with the blank control group (P<0.05), and ** mean significant difference compared with the blank control group (P<0.01); # mean significant difference compared with the PCV2 infection group (P<0.05), and ## mean significant difference compared with the PCV2 infection group (P<0.01). The same as below. |
